Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study.
about
Genetic association analysis of ATP binding cassette protein family reveals a novel association of ABCB1 genetic variants with epilepsy risk, but not with drug-resistanceThe roles of variants in human multidrug resistance (MDR1) gene and their haplotypes on antiepileptic drugs response: a meta-analysis of 57 studiesPolymorphism of ABCB1/MDR1 C3435T in children and adolescents with partial epilepsy is due to different criteria for drug resistance - preliminary results.Homeostatic bioenergetic network regulation - a novel concept to avoid pharmacoresistance in epilepsy.Challenges and recommendations for conducting epidemiological studies in the field of epilepsy pharmacogeneticsInfluence of ATP-binding cassette polymorphisms on neurological outcome after traumatic brain injury.PharmGKB summary: phenytoin pathway.Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysisThe influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.Genetic variability in glutamic acid decarboxylase genes: associations with post-traumatic seizures after severe TBI.CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescentsEpilepsy pharmacogenetics.Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches.Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis.Drug resistance in epilepsy and the ABCB1 gene: The clinical perspective.Genetic biomarkers in epilepsy.Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Intractable epilepsy and the P-glycoprotein hypothesis.Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.New developments in antiepileptic drug resistance: an integrative viewBiomarkers for antiepileptic drug response.CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.Association between ABCB1 polymorphisms and response to First-generation antiepileptic drugs in a Tunisian epileptic population.Vitamin B6 and homocysteine levels in carbamazepine treated epilepsy of Khyber Pakhtunkhwa.Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese.MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion.Association of ABCB1 C3435T polymorphism with phenobarbital resistance in Thai patients with epilepsy.ABCC2 haplotype is not associated with drug-resistant epilepsy.
P2860
Q28540047-67818522-B211-4CFC-9E37-ACA05432D777Q28545116-DC18E6FC-406A-4CF8-94DA-EBE238CAE193Q34237989-0139B334-0A09-4055-B797-E11985E464F3Q35072901-DC0E0792-F064-4CE0-9F48-DC5FEFECF804Q35073480-DA58BBA9-FE9E-49AA-9A3A-FAB1EDD77390Q35095391-8AEAF2EC-7DAE-4F06-B92A-1C91E51C8505Q35950546-A4D580DB-6437-4AE8-A25D-4559559FD4E1Q36281662-74D69E4C-9D8B-4825-8EAB-C1909828F3C5Q36528151-E87B2359-7556-4B0F-80E7-5017FE232B55Q36675876-8987B219-A164-4BD6-986F-3CD1F7AFA0B9Q37104987-8AE38C47-0B73-4FDD-A52F-FAC4AB7AA8C2Q37486720-DE4A1E50-2CA1-4F73-976C-AE2E7EBE496CQ37806763-BF8EC59E-5509-435C-BE3A-FABBD6A86638Q37851513-B9AB70C6-8783-44CD-A6BC-497035D9D1DAQ37900131-95572704-665D-41AC-A7DB-480BB3318101Q38190879-8BD9E008-8A25-4B80-87B8-A0C289416204Q38243832-32DAE753-13F0-431E-BDC2-13CF1FD564D9Q38414396-D8AE389A-81B6-4C86-BACA-664162C99939Q38497941-7344BF13-562B-4AC5-88AE-95D3B64C6E82Q38651234-7D84956D-73DF-45F2-A592-8E911F19E7E7Q39981787-ADC8CF13-8D57-4521-81D3-FBC5F8F7FC0BQ40575037-2580F986-A3FF-44C9-9361-BA5D24D1627CQ41631036-4117E731-8795-40FE-B31E-28E7556BBD1BQ42985589-52A3D335-5742-48F3-B66E-48DFEAB2AC9FQ46537046-7F292C32-C811-421C-9687-33249A7CC28EQ47120159-D62E263C-3566-4579-AB19-BE618F8CA20EQ47778592-1205EE1C-2CEB-4743-B08C-594303FC57AEQ47778603-9BE87EFC-87B2-4FB0-B019-A025AA1BBAB1Q49118555-5A9C7A56-C5EE-4FE6-A7DA-2E3C976FAA6BQ51891830-F796B349-4E4A-4D78-A1FF-BAD7846EAB34
P2860
Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Therapeutic drug monitoring an ...... olymorphism perspective study.
@en
type
label
Therapeutic drug monitoring an ...... olymorphism perspective study.
@en
prefLabel
Therapeutic drug monitoring an ...... olymorphism perspective study.
@en
P2093
P1476
Therapeutic drug monitoring an ...... olymorphism perspective study.
@en
P2093
Abdel-Hameed I Mohammed Ebid
Mona M M Ahmed
Samah A Mohammed
P304
P356
10.1097/FTD.0B013E318067CE90
P577
2007-06-01T00:00:00Z